Here are four things to know:
1. Mr. Kennedy joined Histogenics in 2013 as senior vice president of technical operations.
2. Before that, he served as the executive vice president, research and development, at Mascoma, a biofuel company.
3. He has also held several senior leadership roles in technical operations at Genzyme, a biopharmaceutical company.
4. Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.
More articles on devices:
Smith & Nephew Q2 revenue up 5%: 8 things to know
5 key notes on NuVasive’s 10% share growth yesterday — What it means going forward
SeaSpine Q2 revenue down 6% in first report as independent company: 6 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
